Experienced in Lung Metastases

Janusz Milanowski

Lublin, LU, PL 
Experienced in Lung Metastases
Lublin, LU, PL 
OverviewLocationsClinical Research

Overview

Janusz Milanowski practices in Lublin, Poland. Mr. Milanowski is rated as an Experienced expert by MediFind in the treatment of Lung Metastases. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Hypersensitivity Pneumonitis, EGFR Positive Lung Cancer, and Bone Marrow Transplant.

His clinical research consists of co-authoring 159 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Lung Metastases.

Gender
Male

Locations

Lublin, LU 20954, Poland
Other Locations
Lubin, DS 20954, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

159 Total Publications

MET and SLFN11 as a Players in the SCLC Molecular Subtyping Game.
MET and SLFN11 as a Players in the SCLC Molecular Subtyping Game.
Journal: International journal of molecular sciences
Published: May 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Milanowski's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile